Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of “Hold” by Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have received a consensus recommendation of “Hold” from the six ratings firms that are covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $10.00.

AGEN has been the subject of several analyst reports. B. Riley decreased their price objective on shares of Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, August 14th. HC Wainwright decreased their target price on Agenus from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Tuesday, November 12th. Finally, StockNews.com cut shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th.

Agenus Stock Up 3.9 %

NASDAQ AGEN opened at $2.67 on Thursday. Agenus has a 52 week low of $2.50 and a 52 week high of $19.69. The firm has a market capitalization of $62.64 million, a price-to-earnings ratio of -0.24 and a beta of 1.39. The company has a fifty day moving average of $4.53 and a two-hundred day moving average of $8.46.

Institutional Investors Weigh In On Agenus

Several hedge funds have recently modified their holdings of AGEN. Barclays PLC boosted its holdings in shares of Agenus by 295.3% in the 3rd quarter. Barclays PLC now owns 27,813 shares of the biotechnology company’s stock valued at $152,000 after buying an additional 20,777 shares in the last quarter. Geode Capital Management LLC boosted its stake in Agenus by 7.1% in the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock valued at $2,648,000 after acquiring an additional 32,016 shares in the last quarter. EP Wealth Advisors LLC purchased a new position in Agenus in the third quarter worth $55,000. State Street Corp increased its position in shares of Agenus by 2.1% during the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after purchasing an additional 9,731 shares in the last quarter. Finally, Point72 DIFC Ltd lifted its holdings in shares of Agenus by 380.0% during the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 11,542 shares during the last quarter. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.